Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 8/20 | 0.55 |
| ▸ | PLAU | P00749 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 3/20 | 0.53 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | HPN | P05981 | 2/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286589 | 0.94 | F2 (0.53) | MEN1MAPTKMT2ASMN1; SMN2NAMPT | |
| SCHEMBL6276930 | 0.92 | CA2 (0.53) | MEN1MAPTKMT2ASMN1; SMN2TSHR | |
| SCHEMBL6276427 | 0.90 | GPR55 (0.56) | MEN1MAPTKMT2ASMN1; SMN2F2 | |
| SCHEMBL6280114 | 0.87 | NAMPT (0.62) | MEN1MAPTKMT2ASMN1; SMN2NAMPT | |
| SCHEMBL6285904 | 0.86 | NAMPT (0.56) | MAPTKMT2ASMN1; SMN2NAMPTF2 | |
| SCHEMBL6281156 | 0.85 | TSHR (0.65) | MEN1MAPTKMT2ASMN1; SMN2NAMPT | |
| SCHEMBL12010884 | 0.85 | NAMPT (0.72) | MEN1MAPTKMT2ASMN1; SMN2NAMPT | |
| SCHEMBL2762224 | 0.83 | PLAU (0.55) | MEN1MAPTKMT2ASMN1; SMN2NAMPT | |
| SCHEMBL6285345 | 0.83 | F2 (0.47) | MEN1MAPTKMT2APLAUF2 | |
| SCHEMBL6276432 | 0.82 | CYP2D6 (0.47) | MEN1MAPTKMT2ASMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949567-B2 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1395548-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2003-06-26 | — | — | US | disclosed |
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2002-11-07 | — | — | US | disclosed |
| WO-2002070467-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | PKD2, PPOX, PKD1 | MEN1 2642/4885MAPT 2767/4885KMT2A 2215/4885 |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | CLIC1, PKD2, PKD1 | MEN1 1654/4885MAPT 2803/4885KMT2A 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.